ENDOVASC LTD INC
SB-2, EX-27, 2000-06-30
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ENDOVASC LTD INC, SB-2, EX-23, 2000-06-30
Next: WALLSTREET RACING STABLES INC, SC 13D, 2000-06-30



<TABLE> <S> <C>

<ARTICLE>                      5
<MULTIPLIER>                   1

<S>                                                                      <C>
<PERIOD-TYPE>                                                            9-MOS
<FISCAL-YEAR-END>                                                                                 JUN-30-1999
<PERIOD-END>                                                                                      MAR-31-2000
<CASH>                                                                                                      0
<SECURITIES>                                                                                                0
<RECEIVABLES>                                                                                               0
<ALLOWANCES>                                                                                                0
<INVENTORY>                                                                                                 0
<CURRENT-ASSETS>                                                                                      198,345
<PP&E>                                                                                                 20,232
<DEPRECIATION>                                                                                          9,959
<TOTAL-ASSETS>                                                                                        211,518
<CURRENT-LIABILITIES>                                                                                 511,764
<BONDS>                                                                                                     0
                                                                                       0
                                                                                                 0
<COMMON>                                                                                               13,864
<OTHER-SE>                                                                                           (341,683)
<TOTAL-LIABILITY-AND-EQUITY>                                                                          211,518
<SALES>                                                                                                     0
<TOTAL-REVENUES>                                                                                       24,283
<CGS>                                                                                                       0
<TOTAL-COSTS>                                                                                       1,810,486
<OTHER-EXPENSES>                                                                                            0
<LOSS-PROVISION>                                                                                            0
<INTEREST-EXPENSE>                                                                                     30,526
<INCOME-PRETAX>                                                                                    (1,786,203)
<INCOME-TAX>                                                                                                0
<INCOME-CONTINUING>                                                                                (1,786,203)
<DISCONTINUED>                                                                                              0
<EXTRAORDINARY>                                                                                             0
<CHANGES>                                                                                                   0
<NET-INCOME>                                                                                       (1,786,203)
<EPS-BASIC>                                                                                             (0.16)
<EPS-DILUTED>                                                                                           (0.16)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission